Lucentis

Showing 9 posts of 54 posts found.

Novartis’ Lucentis recommended for wider EU licence

October 25, 2010
Sales and Marketing CHMP, Genentech, Lucentis, Novartis, diabetic macular edema, ranibizumab

Novartis’ Lucentis has been recommended for approval in Europe to treat people suffering from vison loss due to diabetes. The …

Lucentis boosted by diabetic vision study

May 24, 2010
Research and Development, Sales and Marketing AMD, DME, Lucentis, Novartis

A phase III trial of Novartis’ ranibizumab has shown it to be superior at promoting vision gain in patients with …

NICE bends to pressure over Lucentis

December 14, 2007
Sales and Marketing AMD, Lucentis, NICE

NICE is set to change its guidance for blindness treatment Lucentis following a barrage of complaints over its failure to …

NICE to re-think blindness drugs decision

August 9, 2007
Sales and Marketing AMD, Lucentis, Macugen, NICE

NICE will delay issuing final guidance on two blindness drugs after an unprecedented patient outcry over its decision to block …

NICE set to block blindness drugs

June 15, 2007
Sales and Marketing AMD, Lucentis, Macugen, NICE

Most patients in England and Wales will be denied access to drugs for the leading cause of sight loss if …

Lucentis approved in Europe

January 26, 2007
Sales and Marketing Lucentis, Novartis

European regulators have approved Novartis’ Lucentis, a new treatment for neovascular age-related macular degeneration, known as wet AMD.The company says …

New blindness treatment moves closer to market

November 28, 2006
Sales and Marketing AMD, Lucentis, Novartis

Patients suffering from the leading cause of blindness could soon benefit from a new treatment after it gained preliminary approval …

New Novartis blindness treatment filed in Europe

March 2, 2006
Sales and Marketing AMD, Lucentis, Novartis

Lucentis, a new treatment for neovascular age-related macular degeneration or ‘wet AMD’ has been submitted by Novartis to the European …

The Gateway to Local Adoption Series

Latest content